GlobeNewswire Inc | Nov 11, 2020 02:51PM EST

November 11, 2020

NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of NextCure, Inc. (NASDAQ: NXTC) (1) between November 5, 2019 and July 14, 2020, inclusive (the Class Period); and/or (2) pursuant or traceable to NextCures November 2019 secondary public offering.

To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=nextcure-inc&id=2447 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or emailinfo@zhanginvestorlaw.comfor information on the class action.

http://zhanginvestorlaw.com/join-action-form/?slug=nextcure-inc&id=2447

If you wish to serve as lead plaintiff, you must move the Court before the November 20, 2020 DEADLINE. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) NextCure possessed NC318 data that showed a lack of efficacy and objective responses; (2) NC318 was not, in fact, effective in treating most tumor types; (3) the NC318 application was proving to be limited (if even useful at all); (4) as a result of the foregoing, there was a significant realizable risk that NC318 would not be nearly as popular as then-existing blockbuster drugs, such as Keytruda; and (5) as a result, defendants public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Lead plaintiff status is not required to seek compensation. You may retain counsel of your choice. You may remain an absent class member and take no action at this time.

Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes.

Zhang Investor Law P.C.99 Wall Street, Suite 232New York, New York 10005info@zhanginvestorlaw.comtel: (800) 991-3756